Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease

por Zachariae, R, Pedersen, C G, Jensen, A B, Ehrnrooth, E, Rossen, P B, von der Maase, H
Publicado 2003

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

por Steele, N, Anthony, A, Saunders, M, Esmarck, B, Ehrnrooth, E, Kristjansen, P E G, Nihlén, A, Hansen, L T, Cassidy, J
Publicado 2012

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)

por Seiwert, T. Y., Fayette, J., Cupissol, D., del Campo, J. M., Clement, P. M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., Cohen, E. E. W.
Publicado 2014

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(...

por Clement, P. M., Gauler, T., Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Cohen, E. E. W., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J. M., Cong, X. J., Ehrnrooth, E., Vermorken, J. B.
Publicado 2016

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

por Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., Grau, J. J., del Campo, J. M., Mailliez, A., Haddad, R. I., Vermorken, J. B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M. C., Dupuis, N., Krämer, N., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P. H.
Publicado 2017